Published: 16 May 2025
Text: Anne-Marie Korseberg Stokke
)
ARTBIO, a clinical-stage radiopharmaceutical company developing a new class of alpha radioligand therapies (ARTs), have relocated their European research labs to Oslo Science Park in Oslo, Norway. The move provides ARTBIO with improved development lab facilities and preclinical expertise, particularly in the radiotherapeutic space, to help advance the company’s pipeline of ARTs and strengthen ARTBIO’s radiation-enabled R&D. In addition, the move reflects ARTBIO’s commitment to the highest standards of medical quality and safety.
"ARTBIO is redefining cancer care by developing a new class of alpha radioligand therapies, and the new facility at Oslo Science Park enables us to advance our research,” says Emanuele Ostuni, Ph.D., CEO of ARTBIO.
“Our presence will enhance our team’s capabilities and facilitate expansion by leveraging the unique radiopharmaceutical expertise found in Oslo. Our research programs in Oslo complement the ongoing work happening elsewhere at ARTBIO.”
Headquartered in Cambridge, Massachusetts, USA, with branches in Switzerland, the UK, and Norway, ARTBIO’s decision to relocate their research center to Oslo Science Park stems from a strategic focus to bolster the company’s radiopharmaceutical R&D and advance its proprietary technology development as well as preclinical biology research aimed at developing novel cancer treatments. The company also anticipates contributing significantly to the broader academic and scientific radiopharmaceutical ecosystem in Norway, aligning with its commitment to redefine cancer care.
“Securing an integrated research facility in Oslo Science Park based on Th and Pb is important for ARTBIO as the state-of-the-art laboratories allow us to advance our research and development efforts efficiently and effectively,” said Philippe Dasse, Pharm.D., Chief Technical Officer at ARTBIO.
"ARTBIO’s foundational proprietary technology has origins in the Oslo ecosystem, so we place a high value on the capabilities and talent available through Oslo Science Park. The opportunity to establish such a specialized facility in Norway is rare, and our presence in this purpose-built research hub not only enhances our R&D capabilities but also ensures we can conduct our work with the highest safety standards."
)
Oslo Science Park offers a world-class life sciences ecosystem, enabling laboratory research ranging from an open shared lab in ShareLab to more sophisticated lab suites and custom facilities for companies such as Vitas, Nykode, Nextera, and GE Healthcare. Research into cancer treatment and medical radiation necessitates highly specialized equipment typically not available in standard labs. COO Hans-Peter Daae and the team at Oslo Science Park have collaborated closely with ARTBIO's team to devise optimal solutions to address specific challenges of safe handling and storing of radiopharmaceutical intermediates and products.
Hans-Peter Daae, COO at Oslo Science Park, emphasises that “despite the complexities of accommodating such laboratories, ARTBIO represents precisely the type of cutting-edge research OSP wishes to attract.”
“ARTBIO will be an exciting addition to the already thriving environment in health and life sciences at Oslo Science Park, one we believe will also greatly benefit and inspire ARTBIO. We take pride in being a development partner and in facilitating this collaboration," says Daae.
“We are excited to join this growing community of researchers and innovators," says Dr. Ostuni.
"Oslo Science Park offers us invaluable support as we advance our novel clinical pipeline and reflects our shared commitment to excellence in cancer research."
)
Cellmover is now making great strides in developing next-generation cancer therapies. The company has recently secured funding through the Eurostars program, and CSO Miriam Aarsund Larsen has been named one of Norway's 50 leading women in technology. How did she transition from researcher to leader, and what is driving Cellmover forward?
)
Artificial intelligence is making its way into the healthcare sector and can help solve the complex scheduling of shifts. The Aleap company Synplan offers an innovative solution that not only makes the job easier, but also improves working conditions and saves resources. It is now being tested at the renowned Mayo Clinic in the US.
)
What does work look like on a bedside ward in a hospital or nursing home? How can digital solutions reduce staffing needs and provide more efficient patient care? At "Tech Scan" in Oslo Science Park, Health2B brought together stakeholders from hospitals, municipalities and the business community to meet and learn from each other.
)
)
)